Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
UCB.BR
HOLDUCB SA · Healthcare · Belgium · $56.0B · Avg Vol: $50M/d
COMPANY DESCRIPTION
UCB SA is a global biopharmaceutical company specializing in severe diseases within immunology and neurology. The company's portfolio features blockbuster treatments like Cimzia and Vimpat, alongside high-growth launches such as Bimzelx for psoriasis. UCB's competitive moat is built on robust R&D capabilities, a specialized commercial footprint, and a deep pipeline of targeted biologic therapies.
FINANCIAL SUMMARY (EUR)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 5.5B | 5.3B | 6.2B | 7.7B | 12.0% | 7.8B | 8.6B | 9.6B | 11.5% |
| EPS (EUR) | 5.60 | 2.20 | 1.81 | 5.61 | 8.20 | 10.0% | 8.05 | 9.08 | 11.18 | 16.8% |
| Shares | — | 189.6M | 189.8M | 190.0M | 190.4M | +0.4% | — | — | — | — |
| Debt | — | 2.9B | 3.0B | 3.0B | 2.2B | -8.2% | 2.2B | — | — | — |
| Equity | — | 9.1B | 9.0B | 10.0B | 10.9B | 6.2% | — | — | — | — |
| Op CF | — | 1.1B | 761.0M | 1.2B | 2.3B | 27.0% | 2.3B | — | — | — |
| Inv CF | — | -1.6B | -440.0M | 282.0M | -389.0M | — | — | — | — | — |
| Fin CF | — | 70.0M | -308.0M | -818.0M | -1.2B | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of UCB.BR are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| UCB.BR | UCB SA(you) | $56.0B | 64 | HOLD |
| ARGX.BR | argenx SE | $55.6B | 64 | HOLD |
| 0QNO.L | Lonza Group AG | $47.0B | 61 | HOLD |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $82.3B | 60 | HOLD |
| 0HAV.L | Agilent Technologies, Inc. | $36.7B | 60 | HOLD |
| 207940.KS | Samsung Biologics Co.,Ltd. | $40.5B | 55 | HOLD |
| RPRX | Royalty Pharma plc | $33.9B | 70 | BUY |
| ONC | BeOne Medicines AG | $33.8B | 70 | BUY |
| 0JDM.L | IQVIA Holdings Inc. | $33.9B | 57 | HOLD |
| 0K10.L | Mettler-Toledo International Inc. | $33.1B | 57 | HOLD |
Peer medians: ROE 2.1% · P/E 23.4x · Gross margin 50.0%